ライフサイエンスコーパス: drug targeting

1 ing sites remain conserved and available for drug targeting.

2 re are in driver genes or genes amenable for drug targeting.

3 at sustain cancer cells and are suitable for drug targeting.

4 cular due to their potential applications in drug targeting.

5 dicting the suitability of each molecule for drug targeting.

6 r poor availability are major bottlenecks in drug targeting.

7 peptides as vehicles for hepatocyte-specific drug targeting.

8 oter G-quadruplex loop isomers and for their drug targeting.

9 multi-photon microscopy studies on OBBBO and drug targeting.

10 raction may lead to improved cancer-specific drug targeting.

11 are potentially useful for isoform-selective drug targeting.

12 not enzymes per se amenable to conventional drug targeting.

13 10, IL-18, and IL-12 p40, and identified 140 drugs targeting 16 of them.

14 small (+)RNA virus, to brefeldin A (BFA), a drug targeting a cellular component of the viral replica

15 The only marketed drug targeting a PAR is vorapaxar, a selective antagonis

16 opportunities and challenges for developing drugs targeting a common mediator that would be benefici

17 patterns of gene response that indicate that drugs targeting a particular gene will be likely or not

18 llular responses, opening the possibility of drugs targeting a receptor subtype in specific brain reg

19 or optimal development and implementation of drugs targeting aberrant AKT activation.

20 mportant implications for the development of drugs targeting Abeta production in Alzheimer disease.

21 py cancer cells are effectively treated with drugs targeting acquired phenotypes.

22 s are beginning to provide novel avenues for drug targeting against infectious agents.

23 at laquinimod may represent a first-in-class drug targeting AhR for the treatment of multiple scleros

24 iomarkers are used as surrogate measures for drug targeting and approval and are generally based on p

25 a membrane-protein-supporting platform, or a drug targeting and delivery vehicle in general, is under

26 membrane protein functions, or involved with drug targeting and delivery.

27 y emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic pro

28 e sugar component(s) to provide benefits for drug targeting and stimuli responsive systems.

29 delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, ha

30 therefore, offers an attractive paradigm for drug targeting and, consequently, the delineation of the

31 m is simple to operate and multiplex to test drugs targeting angiogenesis in a more physiologically r

32 volanesorsen, a second-generation antisense drug targeting apoC-III, were determined in 2 human inte

33 We here present a new drug targeting approach that combines both drug classes

34 eveloping, testing, and ultimately improving drugs targeting AR.

35 oped principles of size-dependent lymph node drug targeting are conserved in melanomas, suggesting th

36 Drugs targeting astrocyte signaling have a potential ben

37 icle (VLP) vaccine as well as small-molecule drugs targeting astrovirus assembly/maturation.

38 t of a VLP vaccine as well as small-molecule drugs targeting astrovirus assembly/maturation.

39 de the development of vaccines and antiviral drugs targeting astrovirus.

40 on way to evaluate the therapeutic effect of drugs targeting atherosclerosis because of an inherent d

41 fute the start of a large-scale M&M trial on drugs targeting atherosclerosis.

42 Drug targeting AXL induces a significant cell killing in

43 hibitor JQ1 combined favorably with multiple drugs targeting B-cell receptor signaling, one pathway t

44 These data imply an efficacy of drugs targeting BAT to treat metabolic disease that is a

45 therapies may profit from combinations with drugs targeting BCR(-) tumour cells.

46 Therefore, drugs targeting beta-chemokines (CCL2 and CCL22), FGF-ba

47 Drugs targeting BK channel represent a potential therape

48 Thus, drugs targeting both WT and the S31N mutant are highly d

49 Drugs targeting calcineurin are potent antifungal agents

50 Thus, repurposing of drugs targeting cancer metabolism might synergistically

51 ty for the development and implementation of drugs targeting cell metabolism and aberrant AKT signali

52 s of this channel and the development of new drugs targeting cellular proton transport.

53 reduces CSD, supporting the possible use of drugs targeting central CGRP receptors as antimigraine a

54 (RO) of MK-0249 and MK-3134, 2 potential IA drugs targeting cerebral H3 receptors, in 6 healthy male

55 r assessments of the therapeutic efficacy of drugs targeting CFTR and provides a value that is in muc

56 Consistently, among 13 drugs targeting chromatin modifiers, EHMT2 inhibitors we

57 Further investigation of drugs targeting chromatin regulators is warranted in HPV

58 accelerate the development of new antiviral drugs targeting cis-acting RNA regulatory signals.

59 Peptide drugs targeting class B1 G-protein-coupled receptors (GP

60 s development of combination treatments with drugs targeting compensatory pathways, will be key to ac

61 Repurposed drugs targeting CPH-mediated metabolic perturbation, suc

62 Contrary to other drugs targeting CXCR4, anti-CXCR4 ADCs effectively elimi

63 However, clinically approved drugs targeting D2 DAR display poor selectivity between

64 en together, the data support the utility of drugs targeting D3/D4 receptors as potential treatments

65 The application of drugs targeting different convulsant mechanisms (4-Amino

66 rs of PKR should be used in combination with drugs targeting directly the inflammasome.

67 nal nanomaterials and the design of anti-HIV drugs targeting (dis)assembly and biocompatible nanocoat

68 elopment of diagnostic tools and therapeutic drugs targeting disease-causing RNAs.

69 d to TSase, which may lead to a new class of drugs targeting DNA biosynthesis.

70 fects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be u

71 a DNA-damage response and sensitizes Mtb to drugs targeting DNA metabolism and respiration.

72 ess conferred a therapeutic vulnerability to drugs targeting DNA-damage repair pathways.

73 potential therapeutic and adverse effects of drugs targeting DRN neurons.

74 Pharmaceutical drugs targeting dyslipidemia and cardiovascular disease

75 e logical postulation that intervention with drugs targeting dysregulated glial proinflammatory cytok

76 formation and suggests that the efficacy of drugs targeting EAD-mediated arrhythmias may depend on t

77 eases, as well as facilitating the design of drugs targeting EBV BILF1.

78 FLIM-FRET) Src biosensor was used to monitor drug-targeting efficacy in a transgenic p53-mutant mouse

79 have been extensively investigated for their drug targeting efficiency towards the critical areas of

80 d that this can be used to map areas of poor drug-targeting efficiency within specific tumor microenv

81 king these models central to structure-based drug targeting efforts.

82 sivelestat, the only approved small molecule drug targeting elastase, which indicated its potential i

83 Treatments include drugs targeting energy intake, energy disposal, lipotoxi

84 ion therapies, the interaction between novel drugs targeting energy metabolism and classical first an

85 In contrast, drugs targeting ERalpha (PPT and MPP), GPR30 (G1 and G15

86 gnaling on myofibrillar organization because drugs targeting ERBB2 (HER2/NEU) signaling, a mainstay o

87 Drugs targeting F508del CFTR and premature termination c

88 2763 is currently being developed as an oral drug targeting ferroportin for the treatment of beta-tha

89 ents with an inflammatory signature, whereas drugs targeting fibrosis are likely to benefit those wit

90 ced atherosclerosis in mice, suggesting that drugs targeting FLNA may be useful in the treatment of a

91 3-ITD-dependent AML results in resistance to drugs targeting FLT3.

92 ss that uses antibodies to improve cytotoxic drug targeting for cancer treatment.

93 5 initiates cancer and demonstrate effective drug targeting for potential therapy of human LGL leukem

94 n of VEGF and are amenable to small molecule drug targeting for VEGF suppression.

95 targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy,

96 human tumours with greater vulnerability to drugs targeting glycolysis.

97 we discuss the current status of the peptide drugs targeting GPCRs, with a focus on evolving strategi

98 es with over one-third of currently marketed drugs targeting GPCRs.

99 Currently, no small-molecule drug targeting GSTO1 is under clinical development.

100 Magnetic drug targeting has been proposed as means of concentrati

101 For example, letermovir is a small-molecule drug targeting HCMV terminase that is currently in phase

102 -animal model for evaluating novel antiviral drugs targeting HCV NS3-NS4A protease and T-cell-based H

103 Here, we identify neratinib, an FDA-approved drug targeting HER2/EGFR dual kinases, as a potent MST1

104 rational design of additional MBP-harboring drugs targeting hGGPPS.

105 Drugs targeting HIF-1alpha are being developed, but the

106 ing and scale-up to industrial level, higher drug targeting, high drug loading, control drug release,

107 This may suggest that as well as drugs targeting histone modifications, it will be valuab

108 nd 9 also inhibited HIV strains resistant to drugs targeting HIV reverse transcriptase, protease, int

109 Statins are cholesterol-lowering drugs, targeting HMG-CoA reductase, thereby reducing the

110 The use of antiviral drugs targeting host proteins required for viral replica

111 m behavioral suppression and discovered that drugs targeting human NPY receptors modulate mosquito ho

112 -promoting pathways in glioblastoma and that drugs targeting Id-1 represent a novel and promising str

113 The success and safety profile of drugs targeting IL -1 in the treatment of CAPS and DIRA

114 engineering of ligands, enabling studies of drug targeting in animal species and subsequent use in h

115 diated endocytosis, provide a new avenue for drug targeting in disorders with aberrant regulation of

116 a partial picture of available receptors for drug targeting in vivo is provided.

117 a purely chemical means to achieve selective drug targeting in vivo.

118 This mechanism has critical implications for drug-targeting in multidrug-resistant tumors where a str

119 Drugs targeting individual G protein-coupled receptors a

120 development of personalized therapy for SSc; drugs targeting inflammation are likely to benefit those

121 block anaphylaxis, an important feature for drugs targeting inflammatory disease in general.

122 Rational design of pharmaceutical drugs targeting integral membrane G protein-coupled rece

123 r shows that raltegravir, the antiretrovirus drug targeting integrase, is effective against various h

124 Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil grow

125 decades after the successful development of drugs targeting intracellular folate metabolism, such as

126 ves the way for the design of new antibiotic drugs targeting l,d-transpeptidases.

127 that cell phenotype dictates the response to drugs targeting lipid metabolism.

128 provide critical insights for development of drugs targeting LTA4H.

129 est of lesional macrophages, suggesting that drugs targeting macrophage proliferation may be useful i

130 Drugs targeting macrophage TLR8-linked signaling pathway

131 Diverse drugs targeting malignant and nonmalignant cells receive

132 and screening of lung cancers, (ii) magnetic drug targeting (MDT) through either intravenous injectio

133 rs influencing mortality; with this in mind, drug-targeting mechanisms involved in liver injury shoul

134 Drugs targeting mechanisms involved in severe malaria pa

135 a process for dissecting the complexities of drug targeting mediated by nanoparticulate carriers.

136 erapies, including checkpoint inhibitors and drugs targeting MEK or PI3K, can be used in combination

137 ance of 4-quinolinamines as a novel class of drugs targeting membrane biogenesis via inhibition of PS

138 Drugs targeting metabolism have formed the backbone of t

139 Drugs targeting metabotropic glutamate receptor 5 (mGluR

140 w insights into the mechanisms through which drugs targeting mGlu II receptors alleviate hypoglutamat

141 Drugs targeting molecular alterations (IDH2 mutations, s

142 We anticipate that rational development of drugs targeting molecular chaperones might help in futur

143 However, attempts to develop anti-chaperone drugs targeting molecules such as Hsp70 have been hamper

144 isease that can successfully be treated with drugs targeting mutant onco-proteins has motivated whole

145 ations of recently disclosed investigational drugs targeting Na(V)1.7 and review evidence that, by be

146 Yet to date, FDA-approved drugs targeting NRF2 activity in cancer have not been re

147 ulation, and to support the discovery of new drugs targeting NRs.

148 cessful proof-of-concept study suggests that drugs targeting NS4B may represent a viable treatment op

149 hese activities should help in the design of drugs targeting nsp1.

150 may also be needed in patients treated with drugs targeting NTCP.

151 tigational use in the clinic, relatively few drugs targeting nucleic acid sensors are approved for th

152 lts suggest a rational strategy for enhanced drug targeting of Bcr-Abl and other multidomain kinase s

153 e essential core of the glideosome, enabling drug targeting of both of its core components to inhibit

154 tudy provides proof of concept for selective drug targeting of proximal tubular cells on the basis of

155 m a multifactorial origin, thus conventional drug targeting of single proteins may not prove most eff

156 Accordingly, any potential drug targeting of this gene product must be strictly ass

157 Selective drug targeting of this osteoblast signaling pathway may

158 rapy, radiation therapy, and, more recently, drugs targeting oncogenes, have earned their place only

159 ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

160 can also be distinguished, and we find that drugs targeting only VEGFRs (Apatinib and Vandetanib) ar

161 door to the rapid development of additional drugs targeting other disease-associated genes in the sa

162 ion, might be used in combination with other drugs targeting other mechanisms of disease, although ad

163 light of recent clinical trials that employ drugs targeting p110delta in certain cancers and other d

164 rombus formation, and several antithrombotic drugs targeting P2Y12R--including the prodrugs clopidogr

165 The data may affect the design of drugs targeting Parp proteins and the improvement of rad

166 iPSC-CMs using tacrolimus and rosiglitazone, drugs targeting pathways predicted to produce cardiotoxi

167 Several drugs targeting PI3K/ATK are currently in clinical trial

168 Few drugs targeting picornaviruses are available, making the

169 should help the design of novel antimalarial drugs targeting Plasmodium sexual stages.

170 These results highlight the potential of drugs targeting posttranslational modifications to resto

171 Though there are many anti-cancer drugs targeting primary tumor growth, anti-metastatic ag

172 al importance and analyze the development of drugs targeting protein phosphatases.

173 s) network, which sensitizes cancer cells to drugs targeting protein quality control (PQC) regulators

174 is scalable for high-throughput screening of drugs targeting protein-protein interactions.

175 cations for the discovery and development of drugs targeting receptors such as the calcium-sensing re

176 ercoming the resistance against experimental drugs targeting Ref-1 activity, with clear translational

177 dormancy and may facilitate the discovery of drugs targeting relapsing malaria.

178 r the development of effective antibacterial drugs targeting RNase E.

179 Drugs targeting RR are mainly nucleoside in nature.

180 Drugs targeting S1P signaling have been remarkably succe

181 ally available antileukemic and antilymphoma drugs targeting SCD1 have been reported.

182 (2) Resistance to drugs targeting secreted compounds downstream of QS for

183 y distinct 5-HT receptors, could explain why drugs targeting serotonin function can cause either diab

184 be shared between the two genders for a few drugs targeting sex-specific cancers (e.g., PD-0332991 f

185 f shedding and may aid in the development of drugs targeting sheddases.

186 Development of drugs targeting SNAT2 may be of value for a subset of ho

187 ents the ideal attributes of a promising new drug, targeting specific tissues based on chemotactic cu

188 and clinical trial testing of several novel drugs targeting specific CFTR mutations.

189 opportunities for structure-based design of drugs targeting specific nicotinic acetylcholine recepto

190 of PP2A-inhibitors as potent antiangiogenic drugs targeting specifically nascent blood vessels with

191 gths and weaknesses and describing potential drug targeting strategies to interfere with Hh signaling

192 r-more-sophisticated animal models and newer drug targeting strategies, should promote novel therapeu

193 able controversy on the practical outcome of drug targeting strategies.

194 guide protein engineering, formulation, and drug-targeting strategies that prevent aggregation.

195 ients with ADC may benefit from antifibrotic drugs targeting stromal TGFbeta1/SMAD3.

196 Omics and drug-targeting studies revealed that PI3Ks act to reduce

197 Drugs targeting such epigenetic mechanisms may open ther

198 e necessary steps toward achieving efficient drug targeting systems.

199 To identify drugs targeting tau neurotoxicity, we have used a Caenor

200 ndidates for multiplex vaccines and/or novel drugs targeting TEMs in the schistosome tegument.

201 Drug targeting that reverses miR-29b repression cures ot

202 ponse of MCTS following UNC1999 treatment, a drug targeting the enzymes that catalyze H3K27me3, namel

203 tive treatment with etanercept, a biological drug targeting the TNF pathway and suppressing inflammat

204 ool would assist in the development of novel drugs targeting the 5-HT6 receptor.

205 the way for the development of new selective drugs targeting the amyloidogenic proteins implicated in

206 g hypertensive disorders when small-molecule drugs targeting the AT1R are contraindicated, for exampl

207 romiscuity and consequent adverse effects of drugs targeting the ATP binding site.

208 y, underscoring the therapeutic potential of drugs targeting the brain's eCB system.

209 litate rational structure-based discovery of drugs targeting the cannabinoid system.

210 While effective anti-cancer drugs targeting the CHK1 kinase are advancing in the cli

211 ke inhibitors are the most widely prescribed drugs targeting the CNS with acute and chronic effects i

212 Whether novel drugs targeting the constitutively active JAK2/STAT path

213 this study, we observed that the potency of drugs targeting the cytochrome bc(1):aa(3) is influenced

214 ch appeared to be particularly essential for drugs targeting the cytochrome bc(1):aa(3) terminal oxid

215 be considered in the clinical development of drugs targeting the cytochrome bc1 :aa3 , as well as for

216 Osteoporosis is currently treated with drugs targeting the differentiation or viability osteocl

217 Anti-cancer drugs targeting the DNA damage response (DDR) exploit ge

218 of vaccine strategies and the development of drugs targeting the early stages of Hepatitis C virus (H

219 nce, great efforts have been made to develop drugs targeting the EET pathway.

220 drugs has distinct properties compared with drugs targeting the endogenous (orthosteric) ligand-bind

221 Drugs targeting the epigenome are new promising cancer t

222 we show that subinhibitory concentration of drugs targeting the F(1)F(0) ATP synthase and the cytoch

223 ovide a template for designing more specific drugs targeting the folate receptor system.

224 eutic exploitation of the next generation of drugs targeting the genetic basis of cancer will require

225 eful in efforts to develop clinically useful drugs targeting the HIV-1 capsid.

226 , and alerts us to the potential toxicity of drugs targeting the IL-6R.

227 Consequently, drugs targeting the inactive or guanosine 5'-diphosphate

228 ful for further development of peptide-based drugs targeting the MDM2/p53 interaction.

229 ead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion ont

230 alized treatment of affective disorders with drugs targeting the metabotropic glutamate receptor 3.

231 m min(-1)) and also predicted the effects of drugs targeting the motor-clutch system or cytoskeletal

232 on of indenoisoquinolines as a new family of drugs targeting the MYC promoter G-quadruplex for MYC su

233 Several drugs targeting the myostatin pathway have been used in

234 Drugs targeting the orthosteric, primary binding site of

235 t would be useful for evaluation of glaucoma drugs targeting the outflow pathway.

236 resistance to fulvestrant can be overcome by drugs targeting the PI3K pathway.

237 All clinically approved drugs targeting the plasmalemmal transporters for dopami

238 In recent years, a number of drugs targeting the prostate-specific membrane antigen (

239 mycin and for the design of novel allosteric drugs targeting the proteasome.

240 Food and Drug Administration (FDA)-approved drugs targeting the related human immunodeficiency virus

241 Development of drugs targeting the ribosome, the site of protein synthe

242 e MRI features may be imaging biomarkers for drugs targeting the ribosome.

243 The wide range of drugs targeting the serotonergic system could be useful

244 disease states to allow rational choices of drugs targeting the specific peptidase of interest.

245 We demonstrate here in silico that drugs targeting the specific RNA-capsid protein contacts

246 malian cell DNA replication, indicating that drugs targeting the terminase complex could be safe and

247 based rational development of small molecule drugs targeting the VEGF G-quadruplex for gene suppressi

248 aripiprazole, and risperidone, and of kinase drugs targeting the VEGF receptor, demonstrates how unde

249 olon cancer-bearing mice (CT26) treated with drugs targeting the VEGF/VEGFR axis.

250 s the possibility of using clinically tested drugs, targeting the Wnt/beta-catenin pathway, for the n

251 h ADC may be more responsive to antifibrotic drugs targeting their stromal TGFbeta1/SMAD3 activation.

252 Drugs targeting these enzymes have attracted interest fo

253 of inhibitors has limited the development of drugs targeting these enzymes.

254 efly discuss the ongoing clinical trials for drugs targeting these factors.

255 olecular basis for clinically developing new drugs targeting these gene mutations for GIST therapy.

256 Importantly, drugs targeting these GPVI signaling pathways are alread

257 urinergic processes and development of novel drugs targeting these pathways could lead to effective t

258 is article, we review efforts to develop new drugs targeting these processes, including agents that r

259 Clinical efficacy trials of drugs targeting these proteins must use endpoints that a

260 tant regulators of airway cell function, and drugs targeting these receptors are among the first line

261 fied that may be useful in the design of new drugs targeting these receptors.

262 ition is critical for the rational design of drugs targeting these tissues.

263 cance for the design of novel AD therapeutic drugs targeting this APP domain.

264 ht reveal the pharmacodynamic (PD) effect of drugs targeting this cancer-specific metabolic pathway.

265 is for the development of novel antidiabetic drugs targeting this class of receptors.

266 inherent advantages over currently available drugs targeting this enzyme.

267 model of the T6SS will facilitate design of drugs targeting this highly prevalent secretion apparatu

268 rentiation, migration, and identity and that drugs targeting this metabolism pathway will impact on t

269 Drugs targeting this pathway are used clinically, but tu

270 investigated the effect of immunosuppressive drugs targeting this pathway, the JAK inhibitor tofaciti

271 eful in the development of anti-tuberculosis drugs targeting this pathway.

272 ther advance the development of antidiabetic drugs targeting this protein.

273 ework to optimize the development and use of drugs targeting this signaling pathway.

274 e responsible for parasite transmission, and drugs targeting this stage are needed to support malaria

275 nd thus the potential efficacy of envisioned drugs targeting this tissue to treat metabolic disease.

276 and molecular basis for future discovery of drugs targeting this TMA-producing enzyme in human gut.

277 Drug targeting those networks, in combination with BRAF

278 n help to identify new or repurpose existing drugs targeting those proteins.

279 as new lead compounds for the development of drugs targeting TLR4 activation and signaling in infecti

280 Drug delivery systems are required for drug targeting to avoid adverse effects associated with

281 Drug targeting to cellular receptors involved in endocyt

282 Drug targeting to inflammatory brain pathologies such as

283 al as a means of enhancing immunotherapy via drug targeting to lymphocytes and lymph nodes.

284 translational efforts towards local vascular drug targeting to the brain.

285 corporated in Sap inhibitors for Candidiasis drugs targeting to lysosomes.

286 Anticancer drugs targeting TOP2 (TOP2 poisons) prevent religation o

287 In addition, side effects of anticancer drugs targeting TOP2A could result from inhibition of TO

288 ons for the development of anti-inflammatory drugs targeting TPL-2.

289 Several novel drugs targeting TRAIL receptors are currently in clinica

290 The pharmacokinetics of nanoparticle-borne drugs targeting tumors depends critically on nanoparticl

291 Drugs targeting two previously discovered painlessness g

292 Introduction of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF

293 s a stratification tool for future trials of drugs targeting vascular leakage.

294 Ten antiangiogenic drugs targeting VEGF or its receptors are approved for c

295 otherapies that incorporate antiangiogenesis drugs targeting VEGF receptor.

296 Therefore drugs targeting VEGFA/VEGFR-2 are being presently used i

297 ng, we reviewed the development of antiviral drugs targeting viral DNA-packaging motors.

298 will facilitate the development of antiviral drugs targeting viral entry steps but also will lead to

299 This biophysical strategy for drug targeting, which lowers required doses and minimize

300 ontrolled-release drug delivery and improved drug targeting within the eye to increase efficacy and r